Φορτώνει......
Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impact
BACKGROUND: Meningococcal disease remains an important cause of morbidity and mortality worldwide. The first broadly effective vaccine against group B disease (which causes considerable meningococcal disease in Europe, the Americas and Australasia) was licensed in the EU in January 2013; our objecti...
Αποθηκεύτηκε σε:
| Κύριοι συγγραφείς: | , , , |
|---|---|
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Elsevier Science
2013
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3743045/ https://ncbi.nlm.nih.gov/pubmed/23566946 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.vaccine.2013.03.034 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|